1. Frenzel, T., Lengsfeld, P., Schirmer, H., Hütter, J. and Weinmann, H., 2008. Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C. Investigative Radiology, 43(12), pp.817-828.
2. Dotarem [package insert]. Princeton, NJ: Guerbet LLC; Oct2019.
3. Guerbet, Villepinte(FR).Process for preparing a pharmaceutical formulation of Contrast Agents. US 9,655,983 B2, 2017.
4. Baraghini S. Number of doses Dota. 2019.
5. deKervilerE, Maravilla K, Meder J, Naggara O, Dubourdieu C, Jullien V et al. Adverse Reactions to Gadoterate Meglumine. Investigative Radiology. 2016;51(9):544-551.
6. RadbruchA, WeberlingL, Kieslich P, Eidel O, Burth S, Kickingereder P et al. Gadolinium Retention in the Dentate Nucleus and Globus Pallidus Is Dependent on the Class of Contrast Agent. Radiology. 2015;275(3):783-791.
7. Radbruch A, WeberlingL, KieslichP, Hepp J, Kickingereder P, Wick W et al. Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Investigative Radiology. 2016;51(11):683-690.
8. Eisele P, Alonso A, Szabo K, Ebert A, Ong M, Schoenberg S et al. Lack ofincreased signal intensity in the dentate nucleus after repeated administration of a macrocyclic contrast agent in multiple sclerosis. Medicine. 2016;95(39):e4624.
9. Radbruch A, HaaseR, KieslichP, Weberling L, Kickingereder P, Wick W et al. No Signal Intensity Increase in the Dentate Nucleus on Unenhanced T1-weighted MR Images after More than 20 Serial Injections of Macrocyclic Gadolinium-based Contrast Agents. Radiology. 2017;282(3):699-707.
10. Tibussek D, Rademacher C, CaspersJ, TurowskiB, Schaper J, Antoch G et al. Gadolinium Brain Deposition after Macrocyclic Gadolinium Administration: A Pediatric Case-Control Study. Radiology. 2017;285(1):223-230.
11. Hao D, Ai T, Goerner F, Hu X, Runge V, TweedleM. MRI contrast agents: Basic chemistry and safety. Journal of Magnetic Resonance Imaging. 2012;36(5):1060-1071.
*Dotarem was launched globally in 1989 and approved by the FDA for use in the US in 2013.
** Reimbursement information provided is for illustrative purposes only and does not constitute legal advice. Information provided is gathered from third party sources and is subject to change without notice due to frequently changing laws, rules and regulations. Guerbet makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other third party payers as to the correct form of billing or the amount that will be paid to providers of service. The provider of service has the responsibility to determine medical necessity and to submit appropriate codes and charges for care provided. Please contact your local payers, reimbursement specialists and/or legal counsel for interpretation of coding, coverage, and payment policies. Guerbet does not promote the use of its products outside FDA-approved labeling.